Ryota Shibaki, Daichi Fujimoto, Eisaku Miyauchi, Yoko Tsukita, Ichiro Nakachi, Daisuke Arai, Yoshihiko Sakata, Naoki Shingu, Toshio Shimokawa, Takashi Kijima, et al. Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: A multicenter, open-label prospective trial. Lung cancer (Amsterdam, Netherlands). 2024. 196. 107958-107958
Katsuyuki Furuta, Daichi Fujimoto, Atsushi Matsunashi, Ryota Shibaki, Shinnosuke Taniya, Masanori Tanaka, Yuri Shimada, Kazuma Nagata, Keisuke Tomii, Nobuyuki Yamamoto. Prognostic impact of cytokines and chemokines in bronchoalveolar lavage fluid on acute exacerbation of fibrosing interstitial lung disease. Respiratory medicine. 2024. 231. 107721-107721
Daichi Fujimoto, Hidetoshi Hayashi, Kenta Murotani, Yukihiro Toi, Toshihide Yokoyama, Terufumi Kato, Teppei Yamaguchi, Kaoru Tanaka, Satoru Miura, Motohiro Tamiya, et al. Prediction of prognosis in lung cancer using machine learning with inter-institutional generalizability: A multicenter cohort study (WJOG15121L: REAL-WIND). Lung cancer (Amsterdam, Netherlands). 2024. 194. 107896-107896
Masayuki Takeda, Mototsugu Shimokawa, Atsushi Nakamura, Kaname Nosaki, Yasutaka Watanabe, Terufumi Kato, Daisuke Hayakawa, Hiroshi Tanaka, Toshiaki Takahashi, Masahide Oki, et al. Corrigendum to "A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKI and platinum-based chemotherapy" [Lung Cancer 177 (2023) 44-50]. Lung cancer (Amsterdam, Netherlands). 2024. 193. 107852-107852
